Holen Sie sich die Stockscreener-App
1.66
5.06%
0.08
Handel nachbörslich:
1.64
-0.02
-1.20%
Schlusskurs vom Vortag:
$1.58
Offen:
$1.58
24-Stunden-Volumen:
690.09K
Relative Volume:
0.85
Marktkapitalisierung:
$132.36M
Einnahmen:
$63.63M
Nettoeinkommen (Verlust:
$10.62M
KGV:
33.20
EPS:
0.05
Netto-Cashflow:
$-8.64M
1W Leistung:
+12.16%
1M Leistung:
+5.06%
6M Leistung:
-30.54%
1J Leistung:
+76.88%
1-Tages-Spanne:
$1.57
$1.66
1-Wochen-Bereich:
$1.465
$1.66
52-Wochen-Spanne:
$0.89
$3.10
Protalix BioTherapeutics Inc. Stock (PLX) Company Profile
Firmenname
Protalix BioTherapeutics Inc.
Sektor
Branche
Telefon
972 4 988 9488
Adresse
2 Snunit Street, Science Park PO Box 455, Karmiel
Vergleichen Sie PLX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PLX
Protalix BioTherapeutics Inc.
|
1.66 | 122.79M | 63.63M | 10.62M | -8.64M | 0.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Protalix BioTherapeutics Inc. Stock (PLX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-06-08 | Bestätigt | H.C. Wainwright | Buy |
| 2017-04-17 | Bestätigt | Rodman & Renshaw | Buy |
| 2016-04-04 | Eingeleitet | Rodman & Renshaw | Buy |
| 2015-04-23 | Hochstufung | Jefferies | Hold → Buy |
| 2014-11-12 | Bestätigt | R. F. Lafferty | Buy |
| 2014-01-24 | Eingeleitet | R. F. Lafferty | Buy |
| 2012-05-02 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2012-05-02 | Bestätigt | Oppenheimer | Outperform |
| 2012-04-30 | Herabstufung | Auriga | Buy → Hold |
| 2011-10-13 | Eingeleitet | Morgan Joseph | Hold |
| 2011-03-17 | Herabstufung | WBB Securities | Strong Buy → Buy |
| 2010-11-09 | Bestätigt | Oppenheimer | Outperform |
| 2010-10-14 | Bestätigt | UBS | Buy |
| 2009-12-02 | Bestätigt | Hapoalim | Outperform |
| 2009-09-22 | Eingeleitet | Canaccord Adams | Buy |
| 2009-09-02 | Eingeleitet | Hapoalim | Outperform |
| 2008-12-01 | Bestätigt | Oppenheimer | Outperform |
| 2008-03-11 | Eingeleitet | UBS | Buy |
| 2007-11-20 | Eingeleitet | CIBC Wrld Mkts | Sector Outperform |
Alle ansehen
Protalix BioTherapeutics Inc. Aktie (PLX) Neueste Nachrichten
Protalix signals $100M+ Elfabrio royalties by 2030 as Phase II PRX-115 trial advances - MSN
Using data tools to time your Protalix BioTherapeutics Inc. exit2025 Investor Takeaways & Reliable Volume Spike Alerts - Newser
Forecasting Protalix BioTherapeutics Inc. price range with options dataJuly 2025 Analyst Calls & Verified Stock Trade Ideas - Newser
How Protalix BioTherapeutics Inc. stock reacts to Fed policy changesSell Signal & Growth Focused Entry Reports - Newser
Can machine learning forecast Protalix BioTherapeutics Inc. recoveryTrade Exit Summary & Long Hold Capital Preservation Tips - Newser
Why Protalix BioTherapeutics Inc. stock attracts strong analyst attentionMarket Sentiment Summary & Reliable Entry Point Alerts - Newser
Key metrics from Protalix BioTherapeutics Inc.’s quarterly dataMarket Volume Report & Free Community Consensus Stock Picks - Newser
What analysts say about Protalix BioTherapeutics Inc. stockJuly 2025 Price Swings & Advanced Swing Trade Entry Alerts - sundaytimes.kr
Can Protalix BioTherapeutics Inc. deliver consistent EPS growthDividend Hike & Free Reliable Trade Execution Plans - thegnnews.com
What’s the recovery path for long term holders of Protalix BioTherapeutics Inc.Market Growth Review & Community Consensus Trade Signals - Newser
Protalix BioTherapeutics Experiences Strong Revenue Growth, Strategic Partnerships Drive Success - AInvest
Protalix BioTherapeutics Announces Q2 2025 Results, New CFO to Take Over. - AInvest
PLX: New CFO to Take the Reins - Yahoo Finance
When is the best time to exit Protalix BioTherapeutics Inc.IPO Watch & Technical Entry and Exit Tips - Newser
The Psychology of Protalix BioTherapeutics Inc Inc. (PLX) Price Performance: Understanding Market Sentiment - investchronicle.com
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q2 2025 Earnings Call Transcript - Insider Monkey
Protalix BioTherapeutics Inc (PLX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Protalix BioTherapeutics Reports Strong Q2 2025 Results - TipRanks
Protalix Revenue Jumps 16 Percent in Q2 - AOL.com
Protalix BioTherapeutics Inc. stock momentum explainedMarket Activity Report & Weekly Chart Analysis and Guides - Newser
Protalix BioTherapeutics shares rise 2.65% after-hours after reporting a 50% increase in revenues for the first half of 2025. - AInvest
Protalix BioTherapeutics Q2 2025 Earnings Call Transcript: A Detailed Review of Financial Results and Business Update - AInvest
Protalix's Q2 2025: Unpacking Contradictions in Fabry Disease Market Strategy and Clinical Development - AInvest
Transcript : Protalix BioTherapeutics, Inc., Q2 2025 Earnings Call, Aug 14, 2025 - MarketScreener
Earnings call transcript: Protalix Q2 2025 misses EPS, beats revenue expectations - Investing.com Nigeria
Earnings call transcript: Protalix Q2 2025 misses EPS, beats revenue expectations By Investing.com - Investing.com South Africa
Protalix BioTherapeutics lifts revenue on strong Elfabrio demand - Proactive financial news
Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results - PR Newswire
Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025 - PR Newswire
Chart based analysis of Protalix BioTherapeutics Inc. trendsWeekly Gains Report & Weekly Return Optimization Alerts - Newser
Fibonacci Retracement Aligns with Support in Protalix BioTherapeutics Inc.2025 Major Catalysts & Risk Adjusted Buy and Sell Alerts - beatles.ru
Why Protalix BioTherapeutics Inc. is moving today2025 Macro Impact & Breakout Confirmation Trade Signals - Newser
Director’s Bold Move: Major Investment in Protalix Stock - TipRanks
Protalix BioTherapeutics Director Schwartz Aharon Buys 129000 Shares at $1.6/Share. - AInvest
Will Protalix BioTherapeutics Inc. stock go up in YEARHigh Growth Alert System - newsyoung.net
How Protalix BioTherapeutics Inc. stock performs during market volatilitySecure Buy Strategy Based on Risk Parameters - Newser
Reviewing Protalix BioTherapeutics (NYSE:PLX) & Cortexyme (NASDAQ:CRTX) - Defense World
Exit strategy if you’re trapped in Protalix BioTherapeutics Inc.Free Weekly Setup With 3x Return Potential - Newser
Key External Factors That Drive Protalix BioTherapeutics Inc. Stock Price MovementsMinimal Risk Growth Investment Opportunity Analysis - Newser
Top chart patterns to watch in Protalix BioTherapeutics Inc.Short-Term Upside Breakout Forecast System - Newser
Quantitative breakdown of Protalix BioTherapeutics Inc. recent moveFree Real Profit Trade Plan Suggestions - Newser
Financial Contrast: PharmaCyte Biotech (OTCMKTS:PMCBD) and Protalix BioTherapeutics (NYSE:PLX) - Defense World
Protalix BioTherapeutics Earnings: Key Q2 2025 Financial Results and Business Updates Coming August 14 - Stock Titan
Do the Shorts Know Something You Don't? - AOL.com
Are Bears Losing Grip on Protalix BioTherapeutics Inc.Real-Time Analysis With Entry Targets In Progress - beatles.ru
What are the latest earnings results for Protalix BioTherapeutics Inc.Capitalize on emerging market sectors - Jammu Links News
How strong is Protalix BioTherapeutics Inc. company’s balance sheetGet real-time updates on market trends - Jammu Links News
Should I hold or sell Protalix BioTherapeutics Inc. stock in 2025Free Consultation - Jammu Links News
What is Protalix BioTherapeutics Inc. company’s growth strategyAchieve remarkable returns with smart investing - Jammu Links News
How does Protalix BioTherapeutics Inc. compare to its industry peersGet daily updates on promising stocks - Jammu Links News
What makes Protalix BioTherapeutics Inc. stock price move sharplyAchieve consistent double-digit returns - Jammu Links News
Finanzdaten der Protalix BioTherapeutics Inc.-Aktie (PLX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.94%
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):